EventsBHV Partners and Clave, invest in the Valencian company MATCH biosystems

November 27th, 2020by BHV Partnersón-Martínez-Máñez.png

CLAVE and BHV Partners invest in MATCH biosystems, a biotechnology company that develops rapid pathogen detection tests in hospital and veterinary clinical settings.

The objective of MATCH biosystems is the development of a manageable, low-cost, non-invasive test, capable of accurately detecting the pathogen identified as a clinical target in a few minutes. With current devices, it takes between 24 and 72 hours, with the consequent delay in the final diagnosis and the increase in hospital costs. Therefore, the proposition of MATCH biosystems has a clinical validation that presents competitive advantages over current solutions.


see article in:

Valencia Plaza
La Vanguardia

© BHV Partners, 2022. All rights reserved | Legal disclaimer · Privacy policy · Cookies policy

We use our own and third party cookies to improve your experience and to optimize the operation on the web. If you continue browsing we consider that you accept our cookies policy. More information

La configuració de les galetes d'aquesta web està definida com a "permet galetes" per poder oferir-te una millor experiència de navegació. Si continues utilitzant aquest lloc web sense canviar la configuració de galetes o bé cliques a "Acceptar" entendrem que hi estàs d'acord.